NCT04560855

Brief Summary

Currently, COVID+ infected patients who are on ambulatory home monitoring self-assess their health status simply by completing questionnaires and measuring their temperature twice a day. The SECURADOM project proposes to facilitate the follow-up of COVID+ or suspected COVID+ infected patients, followed at home, by collecting clinical signs on a telephone application and to monitor physiological safety parameters (respiratory rate, heart rate, temperature, blood pressure, activity) using connected objects developed by the company WITHINGS. This daily monitoring, which can be transmitted by patients to the doctors in charge of their surveillance, will improve the quality and safety of home monitoring.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2020

Shorter than P25 for all trials

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 14, 2020

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

September 17, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 23, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 12, 2021

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 12, 2021

Completed
Last Updated

May 20, 2021

Status Verified

September 1, 2020

Enrollment Period

4 months

First QC Date

September 17, 2020

Last Update Submit

May 17, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • Sensitivity and Specificity of the patient's aggravation with a logistic regression model

    The sensitivity and specificity of a logistic regression model based on the vital parameters retrieved from the connected devices will be calculated in order to evaluate its performance

    1 year

  • Sensitivity and Specificity of the patient's aggravation with a cluster model

    The sensitivity and specificity of a cluster model based on the vital parameters retrieved from the connected devices will be calculated in order to evaluate its performance

    1 year

Secondary Outcomes (2)

  • Study the evolution of daily patient parameters without aggravation over time

    1 year

  • Subjective assessment of the connected devices

    1 year

Study Arms (1)

Covid19 Patients

Patients diagnosed as COVID-19 positive and managed on an outpatient basis.

Device: Connected devices measurements

Interventions

The patient has to measure everyday several vital parameters like respiration and heart rate during the night with Withings Sleep, temperature with Withings Thermo, arterial pressure with Withings Tensiometer and physical activity with Withings smartwatch.

Covid19 Patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient diagnosed COVID positive with RT-PCR positive or very suggestive symptoms and a contagion (contact with sick subjects) that can be managed on an outpatient basis.

You may qualify if:

  • Adults, men and women, 18 y/o or more
  • Patient diagnosed COVID positive with RT-PCR positive or very suggestive symptoms and a contagion (contact with sick subjects) that can be managed on an outpatient basis.
  • Patient in possession of a smartphone (with Android or iOS) allowing the installation of the Withings Health Mate application
  • Patient with access to an internet connection for the use of Withings connected products at the containment site
  • Voluntary patient who has not objected to his or her participation
  • Patient affiliated to or beneficiary of a social security scheme

You may not qualify if:

  • Pregnant Women
  • Patient with severe symptoms requiring hospitalization as recommended by the French Ministry of Health (23/03/2020)
  • Patient without social protection or affiliated to the AME (State Medical Aid)
  • Person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure (patient under guardianship or curatorship) Articles L1121-5 to L1121-8
  • Patient who, in the judgment of the investigator, may not be cooperative or respectful of the obligations inherent to participation in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

CHU Grenoble-Alpes

Grenoble, Auvergne-Rhône-Alpes, 38043, France

Location

CHU d'Amiens

Amiens, Hauts-de-France, 80054, France

Location

Hôpital d'Instruction des Armées Percy

Clamart, Île-de-France Region, 92140, France

Location

Hôpital d'Instruction des Armées Bégin

Saint-Mandé, Île-de-France Region, 94160, France

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Jean-Louis Pépin, Pr

    CHU Grenoble Alpes

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 17, 2020

First Posted

September 23, 2020

Study Start

September 14, 2020

Primary Completion

January 12, 2021

Study Completion

May 12, 2021

Last Updated

May 20, 2021

Record last verified: 2020-09

Data Sharing

IPD Sharing
Will not share

Locations